EI
DMAC icon

EAM Investors’s DiaMedica Therapeutics DMAC Stock Holding History

EAM Investors’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-91,425
Closed -$619K – 300
2026
Q1 		$619K Hold
91,425
– – 0.07% 247
2025
Q4 		$728K Buy
+91,425
New +$684K 0.08% 238
2023
Q4 		– Sell
-212,512
Closed -$548K – 277
2023
Q3 		$548K Sell
212,512
-57,907
-21% -$186K 0.11% 268
2023
Q2 		$1.17M Buy
+270,419
New +$657K 0.22% 212
2021
Q2 		– Sell
-108,232
Closed -$990K – 346
2021
Q1 		$990K Sell
108,232
-1,753
-2% -$16.4K 0.15% 305
2020
Q4 		$1.11M Buy
+109,985
New +$602K 0.18% 252

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EAM Investors's DMAC Position: Q2 2026 in Review

EAM Investors sold out of DiaMedica Therapeutics (DMAC) in Q2 2026, closing a stake of 91,425 shares — an estimated $619K sold.

EAM Investors first reported a position in DMAC in Q4 2020 and held it in 6 quarters. The position peaked at $1.17M in Q2 2023. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • EAM Investors reported no remaining DiaMedica Therapeutics position as of Q2 2026 after selling out during the quarter.
  • EAM Investors sold 91,425 DiaMedica Therapeutics shares in Q2 2026, an estimated $619K.
  • EAM Investors first reported a position in DiaMedica Therapeutics in Q4 2020 and held it in 6 quarters.
  • EAM Investors's DiaMedica Therapeutics position peaked at $1.17M in Q2 2023.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.